; and (2) in the case of a priority antimicrobial product that is a biological product, the last day of the eleventh year of the exclusivity period described in section 351(k)(7)(A) of the Public Health Service Act applicable with respect to such product. (e) Permitted transactions Except as provided in this section, the holder of a conveyed exclusivity extension period may sell, exchange, convey, or hold for use, such period. (f) Exception A period referred to in paragraph (1) or (2) of subsection (c) shall not be extended under such subsection if the conveyance of an exclusivity extension period pursuant to subsection (a) or the provision of notice under subsection (b) is made later than 4 years prior to the expiration of such period. (g) Limitations (1) Number of awards The Secretary may make not more than 10 awards under subsection (a). (2) Award for prior approved application A drug is not eligible for designation under this section as a priority antimicrobial product if an application for approval or licensure of such drug was approved under section 505(b) or licensed under section 351(a) of the Public Health Service Act before January 1, 2018. (3) Drugs intended for cosmetic purpose A drug is not eligible for designation under this section as a priority antimicrobial product if the drug is intended to promote hair growth or for any other cosmetic purpose. (4) Conveyance date The holder of an exclusivity extension period awarded under or conveyed pursuant to subsection (a) may not convey such period to be applied with respect to a drug unless such drug is or will be first approved under section 505(c) on or after January 1, 2023. (h) Contribution upon conveyance As a condition on the award of an exclusivity extension period to the holder of a drug pursuant to subsection (a), the Secretary shall require the holder, upon any conveyance of the period pursuant to such subsection, in whole or in portions, to make a monetary contribution to the Foundation for the National Institutes of Health that— (1) is in an